CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
Dr. Jane Apperley: Part I: CML—The Changing Landscape of Front-line Therapy
Interview by L Scott Zoeller
20101023
2010 Nov 23
OncologySTAT Editorial Team
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
OncologySTAT Editorial Team. 2010 Nov 23, Interview by L Scott Zoeller
Abstract
Dr. Jane Apperley is Professor of Hemato-oncology, Imperial College London. Part I: First-Line TherapyImatinib vs newer agentsOncologySTAT: Dr. Apperley, would you talk about the changing landscape of front-line therapy for treatment of newly diagnosed chronic-phase chronic myeloid leukemia (CML)? Is the treatment paradigm changing? If so, how will imatinib fit in with the introduction of secondary tyrosine kinase inhibitors (TKIs)?Dr. Apperley: There is no doubt that the front-line therapy for newly...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
